Arcutis Biotherapeutics receives Health Canada approval for a new seborrheic dermatitis treatment, ZORYVE Foam 0.3%.
Arcutis Biotherapeutics has received Health Canada approval for ZORYVE (Roflumilast) Foam 0.3%, a treatment for seborrheic dermatitis in individuals aged 9 and older. This is the first new topical treatment with a unique mechanism of action approved in over 20 years. The foam is steroid-free and aims to benefit over 2 million Canadians with the condition. This approval adds to Arcutis’ expanding dermatology portfolio.
October 18, 2024
5 Articles